Septerna Launches With $100 Million Series A Financing To Expand The Frontier Of Gpcr-Targeted Medicines Using The Native Complex™ Platform
Amount Raised
$100 Million
Round Type
series a
San FranciscoDescription
Septerna, Inc., a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced its launch and Series A financing of $100 million. The Series A financing was led by Third Rock Ventures with significant support by Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital and Logos Capital. Septerna’s proprietary Native ComplexTM Platform recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment which enables industrial-scale drug discovery using novel screening technologies and structure-based drug design for the first time. Septerna is using the Native ComplexTM to overcome historic challenges of reaching the vast untapped potential of GPCR drug targets for a wide range of diseases.